The independent platform for news, articles and advice for professionals in laboratory medicine

Rapid diagnosis of cardiovascular disease

Addenbrooke’s Hospital’s emergency department (ED), part of Cambridge University Hospitals NHS Foundation Trust, is the first UK site to install two Stratus CS 200 Acute Care Diagnostic cardiac analysers. The technology from Siemens Healthcare Diagnostics is enabling rapid diagnosis of cardiovascular disease (CVD) in order to determine an appropriate treatment plan.

“The prevalence of cardiovascular disease means we sought to make it quicker and easier to gain diagnostic results for patients attending the ED who may require admission,” said Rhys Tassell, point-of-care testing (POCT) team lead. “By housing two Stratus CS 200 analysers within the ED, clinicians are able to gain results and formulate a decision as to whether a patient should be discharged or
will need a bed.

The Stratus CS200 analyser features a touchscreen interface, enabling easy navigation of menus as well as a barcode reader to eliminate the need for manual entry. The system also allows results to be reported in dual units, for easy interpretation by clinicians. It delivers a robust cardiac assay menu, including guideline-acceptable sensitive troponin I, which meets the European Society of Cardiology and American College of Cardiology Joint Committee recommendations of 10% CV at the 99th percentile of a normal population.

Other assays include D-dimer (an important test performed in patients with suspected thrombotic disorders) and human chorionic gonadotrophin (beta hCG), which is used as an early pregnancy detection marker to guide diagnostic testing decisions. CardioPhase high-sensitivity C-reactive protein (hsCRP) is available for assessing risk of future cardiovascular disease. NT-proBNP (N-terminal of the prohormone brain natriuretic peptide) aids in the diagnosis and assessment of severity of congestive heart failure and is used for risk stratification of patients with acute coronary syndrome and heart failure. Myoglobin is available for the early diagnosis of myocardial infarction and creatine kinase myocardial band (CK-MB) mass as an alternative to troponin I.
www.siemens.com

Upcoming Events

Participants’ Meeting: UK NEQAS Immunology, Immunochemistry & Allergy

Sheffield Hallam University, City Campus, Howard Street, Sheffield
24 May, 2024

Med-Tech Innovation Expo

NEC, Birmingham
5-6 June, 2024

UK NEQAS Blood Coagulation: Clinical and Laboratory Haemostasis 2024

Sheffield Hallam University
5-6 June, 2024

LabMedUK24

DoubleTree by Hilton Brighton Metropole
10-12 June, 2024

Infection Diagnostics Symposium 2024

IET Austin Court, Birmingham
26-27 June, 2024

SHOT Symposium 2024

Mercure Manchester Piccadilly Hotel
9 July, 2024

Access the latest issue of Pathology In Practice on your mobile device together with an archive of back issues.

Download the FREE Pathology In Practice app from your device's App store

Upcoming Events

Participants’ Meeting: UK NEQAS Immunology, Immunochemistry & Allergy

Sheffield Hallam University, City Campus, Howard Street, Sheffield
24 May, 2024

Med-Tech Innovation Expo

NEC, Birmingham
5-6 June, 2024

UK NEQAS Blood Coagulation: Clinical and Laboratory Haemostasis 2024

Sheffield Hallam University
5-6 June, 2024

LabMedUK24

DoubleTree by Hilton Brighton Metropole
10-12 June, 2024

Infection Diagnostics Symposium 2024

IET Austin Court, Birmingham
26-27 June, 2024

SHOT Symposium 2024

Mercure Manchester Piccadilly Hotel
9 July, 2024

Access the latest issue of Pathology In Practice on your mobile device together with an archive of back issues.

Download the FREE Pathology In Practice app from your device's App store

Step Communications Ltd, Step House, North Farm Road, Tunbridge Wells, Kent TN2 3DR
Tel: 01892 779999
www.step-communications.com
© 2024 Step Communications Ltd. Registered in England. Registration Number 3893025